EVAX Evaxion
Price Chart
Executive Summary
Evaxion announced new Phase 2 data for its AI-designed personalized cancer vaccine EVX-01, showing 86% of vaccine targets triggered a tumor-specific immune response—a rate higher than previously reported methods. The data, to be presented at AACR, also show durable immune responses and de novo T-cell activation, reinforcing the predictive power of its AI-Immunology™ platform.
Actionable Insight
Traders should monitor upcoming three-year clinical data in H2 2026 and watch for potential partnership announcements, especially given the strong immune response correlation with AI predictions. This data strengthens EVAX's platform story, which may attract biotech interest despite small market cap.
Key Facts
- 86% of vaccine targets in EVX-01 triggered a tumor-specific immune response, a record-high rate
- Durable de novo T-cell responses observed, with 86% of responses being novel tumor-specific T cells
- Positive correlation between AI-prediction scores and immune response magnitude confirms platform accuracy
- Phase 2 trial in advanced melanoma combines EVX-01 with KEYTRUDA® (pembrolizumab), showing 75% Objective Response Rate at two years
- Three-year clinical data expected in H2 2026
Financial Impact
Potential re-rating of EVAX based on clinical validation of AI platform and vaccine efficacy; increases likelihood of partnership or licensing interest
Risk Factors
- Clinical outcomes may not improve proportionally despite strong immune response
- High market expectations could lead to sell-off if H2 2026 data disappoints
- Dilution risk given $35M market cap and likely need for future funding
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3276460 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 12, 2026
28d ago
|
6-K
| $4.17 $4.09 | ▼ −1.92% | ▼ −2.00% | $3.73 (−10.55%) |
|
May 12, 2026
28d ago
|
Press Release
| $4.17 $4.09 | ▼ −1.92% | ▼ −2.00% | $3.73 (−10.55%) |
|
May 7, 2026
4w ago
|
6-K
| $4.07 $4.16 | ▲ +2.21% | ▲ +0.71% | $3.73 (−8.35%) |
|
May 4, 2026
5w ago
|
Press Release
| $4.57 $4.23 | ▼ −7.55% | ▼ −10.49% | $3.73 (−18.38%) |
|
Apr 27, 2026
6w ago
|
6-K
| $4.18 $4.57 | ▲ +9.33% | ▲ +8.93% | $3.73 (−10.77%) |
|
Apr 27, 2026
6w ago
|
Press Release
| $4.18 $4.57 | ▲ +9.33% | ▲ +8.93% | $3.73 (−10.77%) |
|
Apr 22, 2026
6w ago
|
6-K
| $4.27 $4.27 | · 0.00% | ▼ −0.05% | $3.73 (−12.65%) |
|
Apr 17, 2026
7w ago
|
6-K
| $4.45 $4.03 | ▼ −9.44% | ▼ −9.99% | $3.73 (−16.18%) |
|
Apr 17, 2026
7w ago
|
6-K
| $4.45 $4.03 | ▼ −9.44% | ▼ −9.99% | $3.73 (−16.18%) |
|
Apr 17, 2026
7w ago
|
Press Release
| $4.45 $4.03 | ▼ −9.44% | ▼ −9.99% | $3.73 (−16.18%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access